Stock Analysis on Net
Stock Analysis on Net

Biogen Inc. (NASDAQ:BIIB)

Paying users zone. Data is hidden behind: .


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey

This is a one-time payment. There is no automatic renewal.

Common-Size Income Statement
Quarterly Data

Beginner level

Biogen Inc., common-size consolidated income statement (quarterly data)

Microsoft Excel LibreOffice Calc
3 months ended: Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Product, net
Revenues from anti-CD20 therapeutic programs
Other
Revenues
Cost of sales, excluding amortization and impairment of acquired intangible assets
Gross profit
Research and development
Selling, general and administrative
Amortization and impairment of acquired intangible assets
Collaboration (profit) loss sharing
Loss on divestiture of Hillerød, Denmark manufacturing operations
Gain (loss) on fair value remeasurement of contingent consideration
Restructuring charges
Acquired in-process research and development
TECFIDERA litigation settlement and license charges
Income from operations
Other income (expense), net
Income before income tax expense and equity in loss of investee, net of tax
Income tax expense
Equity in loss of investee, net of tax
Net income
Net (income) loss attributable to noncontrolling interests, net of tax
Net income attributable to Biogen Inc.

Based on: 10-Q (filing date: 2020-04-23), 10-K (filing date: 2020-02-06), 10-Q (filing date: 2019-10-22), 10-Q (filing date: 2019-07-24), 10-Q (filing date: 2019-04-24), 10-K (filing date: 2019-02-06), 10-Q (filing date: 2018-10-23), 10-Q (filing date: 2018-07-24), 10-Q (filing date: 2018-04-24), 10-K (filing date: 2018-02-01), 10-Q (filing date: 2017-10-24), 10-Q (filing date: 2017-07-25), 10-Q (filing date: 2017-04-25), 10-K (filing date: 2017-02-02), 10-Q (filing date: 2016-10-26), 10-Q (filing date: 2016-07-21), 10-Q (filing date: 2016-04-21), 10-K (filing date: 2016-02-03), 10-Q (filing date: 2015-10-21), 10-Q (filing date: 2015-07-24), 10-Q (filing date: 2015-04-24).

Income statement item Description The company
Income from operations The net result for the period of deducting operating expenses from operating revenues. Biogen Inc.’s income from operations as a percentage of revenues decreased from Q3 2019 to Q4 2019 but then increased from Q4 2019 to Q1 2020 exceeding Q3 2019 level.
Income before income tax expense and equity in loss of investee, net of tax Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Biogen Inc.’s income before income tax expense and equity in loss of investee, net of tax as a percentage of revenues decreased from Q3 2019 to Q4 2019 but then slightly increased from Q4 2019 to Q1 2020.
Net income attributable to Biogen Inc. The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Biogen Inc.’s net income attributable to Biogen Inc. as a percentage of revenues decreased from Q3 2019 to Q4 2019 but then slightly increased from Q4 2019 to Q1 2020.